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Abstract
Background: The tumor microenvironment impacts pancreatic cancer (PC) development, progression and
metastasis. How intratumoral inflammatory mediators modulate this biology remains poorly understood. We
hypothesized that the inflammatory milieu within the PC microenvironment would correlate with clinicopathologic
findings and survival.
Methods: Pancreatic specimens from normal pancreas (n = 6), chronic pancreatitis (n = 9) and pancreatic
adenocarcinoma (n = 36) were homogenized immediately upon resection. Homogenates were subjected to
multiplex analysis of 41 inflammatory mediators.
Results: Twenty-three mediators were significantly elevated in adenocarcinoma specimens compared to
nonmalignant controls. Increased intratumoral IL-8 concentrations associated with larger tumors (P = .045) and poor
differentiation (P = .038); the administration of neoadjuvant chemotherapy associated with reduced IL-8 concentrations
(P = .003). Neoadjuvant therapy was also associated with elevated concentrations of Flt-3 L (P = .005). Elevated levels of
pro-inflammatory cytokines IL-1β (P = .017) and TNFα (P = .033) were associated with a poor histopathologic response
to neoadjuvant therapy. Elevated concentrations of G-CSF (P = .016) and PDGF-AA (P = .012) correlated with reduced
overall survival. Conversely, elevated concentrations of FGF-2 (P = .038), TNFα (P = .031) and MIP-1α (P = .036) were
associated with prolonged survival.
Conclusion: The pancreatic cancer microenvironment harbors a unique inflammatory milieu with potential diagnostic
and prognostic value.
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Background
Pancreatic adenocarcinoma (PC) is the fourth leading
cause of cancer deaths in the United States, due in part
to nearly universal resistance to cytotoxic chemotherapy.
Gemcitabine-based therapies achieve clinical benefit in
approximately 24 % of patients with PC [1], but the
overall survival advantages are sobering, ranging from a
few weeks to months [1–3]. Complete surgical resection
offers patients with PC the greatest survival benefit.
However, this is achievable in fewer than 20 % of pa-
tients presenting with PC [4]. As a result, PC is pro-
jected to be the second leading cause of cancer deaths
by 2030 [5]. There is a tremendous need to discover
novel biomarker (s) or panels of biomarkers that can aid
in detecting PC earlier, improving prognostic evaluation
and predicting response to chemotherapy.
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Inflammation within the PC microenvironment has
been mechanistically linked to tumor progression and
chemoresistance through NF-κB, IL-6, toll-like receptor
and TGF-β signaling pathways [6–10]. However, the
diagnostic and prognostic value of the inflammatory
milieu within the PC microenvironment remains essen-
tially undefined. While survival gains from immune cell
infiltration into the tumor microenvironment have been
conclusively demonstrated in colorectal and ovarian cancer
[11–13], similar investigations have not yielded consistent
results in PC [14, 15]. Patients with chronic pancreatitis are
5–15 times more likely to develop PC [16] and insights into
the association between inflammation and PC stems from
investigations of chronic pancreatitis. Potential environ-
mental sequelae of pancreatitis such as hypoxia, the pres-
ence of reactive oxygen species, and acidosis may
influence the development of PC [17]. Additionally, nu-
merous soluble mediators, including TNF-α [18], TGF-α
[19], TGF-β [20], IL-1β [21], IL-1α [22], IL-6 [23, 24], IL-8
[25], VEGF [26], and others have been implicated in PC
carcinogenesis, tumor progression, and treatment resist-
ance. However, the relationship between the inflammatory
milieu and the spectrum of disease from normal pancreas
to pancreatitis to pancreatic cancer has not yet been char-
acterized. Therefore, the translational relevance of the mi-
croenvironmental inflammatory milieu to PC development
and progression remains speculative.
We examined the inflammatory milieu present in the
PC microenvironment from 36 freshly resected tumor
specimens using a forty-one-item panel of cytokines,
chemokines and growth factors to test the hypothesis
that expression levels of these mediators harbor diagnos-
tic and prognostic value. We first compared the inflam-
matory milieu of PC to that of pancreatitis (n = 9) and
normal pancreas (n = 6). Inflammatory mediators were
further evaluated in relation to prognostic clinicopatho-
logic parameters, administration of neoadjuvant therapy,
treatment resistance and patient survival. These data
bring the field one step closer to the identification of bio-
marker panels that can aid in detecting disease earlier and
classifying patients with respect to response to chemother-
apy and most importantly, prognosis.
Materials and methods
Patient cohorts
A prospectively maintained database approved by the
Institutional Review Board at the University of Florida
(353–2007) was utilized for sample selection. Written
informed consent was obtained from all participants. In
total, 51 samples were included in this study. Using
pathologically verified diagnoses, samples were placed
into one of three experimental groups: normal pancreas
(n = 6), chronic pancreatitis (n = 9) and pancreatic
carcinoma (n = 36). Indications for resection of ‘normal’
pancreata included duodenal adenomas (n = 3), re-
motely located neuroendocrine tumors (n = 2) and a
ductal squamoid cyst (n = 1). Of the 36 patients with
pathologically confirmed pancreatic adenocarcinoma,
all underwent resection with curative intent, 10 whom
completed gemcitabine/abraxane-based neoadjuvant
chemotherapy. Pathologic response to neoadjuvant
chemotherapy was graded by clinical pathologists upon
resection using a validated scale [27]. Briefly, histopath-
ologic response to neoadjuvant therapy was broadly
grouped into complete (>90 % of tumor cells destroyed),
moderate (10–90 % of tumor cells destroyed) and poor
(<10 % of tumor cells destroyed). All 36 patients had at
least 6 months of clinical follow-up for survival analysis.
Pancreatic tissue harvest
Resected pancreatic tissue was immediately weighed and
placed in cell lysis buffer (Cell Signaling Technologies,
Danvers, MA) with a protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO). Immediately adjacent tissues
were preserved in formalin for histologic verification of
pathology. Tissues were dissociated mechanically and
further homogenized using the FastPrep-24 system ac-
cording to the manufacturer’s protocol (MP Biomedicals,
Santa Ana, CA). Homogenates were stored at −80 °C
until soluble mediator analysis could be performed.
Soluble mediator analysis
Homogenates were then probed for soluble mediators
using the Milliplex® Premixed 41-Plex Immunology
Multiplex Assay (Merck Millipore, Darmstadt, Germany)
according to the manufacturer’s protocol. Specifically,
supernatants from tissue homogenates were incubated
in filter bottom microtiter plates (EMD Millipore, San
Jose, CA) with beads coated with primary antibodies over-
night at 4C. After washing, PE- conjugated anti-cytokine
antibodies were added and incubated for additional 2 h at
room temperature. Following washing, data was acquired
on a Luminex 200 (EMD Millipore, San Jose, CA) and
analyzed with Milliplex Software (EMD Millipore, San
Jose, CA). Concentrations were quantified using a stand-
ard curve and 5 parameter logistics to determine pg/mL
concentrations.
All cytokine concentrations were normalized to total
protein concentrations using detergent compatible protein
quantification (Bio-Rad, Hercules, CA). Soluble mediator
concentrations were then converted to pg/mg of tissue as
follows: pg/ml divided by mg/ml of total protein.
Statistical analysis
All statistical analysis was performed using SPSS version
22.0 (IBM SPSS Statistics for Windows; IBM Corp). For
each normalized tissue cytokine concentration, represented
in picograms per milligram of total protein (pg/mg protein),
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normality was assessed using the Shapiro-Wilk test. Since
all normalized cytokine concentrations did not display nor-
mal distributions (P < 0.05), non-parametric testing was
employed to evaluate differences. In this manner, the Mann
Whitney U test was incorporated for binomial categorical
variables, and P < 0.05 was considered statistically signifi-
cant. Additionally, Spearman’s rank correlation coefficients
were employed to determine significant associations be-
tween continuous variables. Overall survival was calcu-
lated using the following formula: Number of days
from date of surgery to death or the date of last follow-
up, whichever came first, divided by 365.25 (account-
ing for leap years), multiplied by 12 to obtain the time
in months. Kaplan-Meier survival curves were gener-
ated using median intratumoral concentration to
dichotomize PC specimens into cytokinehigh and cyto-
kinelow groups. The log-rank (Mantel-Cox) test was
used to evaluate statistical significance. Additionally, a
univariate Cox proportional hazards model was used
to generate hazard ratios. Each soluble mediator was
then incorporated into a multivariate proportional haz-
ards model with the degree of lymphatic metastasis, as
this was the only clinicopathologic parameter demon-
strating a significant correlation with survival (P < .05)
on univariate analysis.
Results
Pancreatic adenocarcinoma has a distinct intratumoral
inflammatory milieu
Establishing the diagnosis of PC remains a significant
clinical problem that delays initiation of therapy, impacts
enrollment in clinical trials, and mandates that patients
undergo major surgical procedures in the absence of
definitive findings. In order to determine whether the
intratumoral inflammatory milieu may have diagnostic
value, we measured the concentrations of 41 cytokines,
chemokines and growth factors in 51 freshly homogenized
pancreatic surgical samples. We found no significant dif-
ferences in any of the normalized cytokine concentrations
when comparing normal pancreatic tissue (n = 6) to that
of chronic pancreatitis (n = 9). Thus, pairwise comparisons
between nonmalignant tissue (n = 15) and adenocarcin-
oma (n = 36) as well as between pancreatitis alone (n = 9)
and adenocarcinoma (n = 36) were performed (Table 1). Of
the 41-protein-panel of cytokines, chemokines and growth
factors evaluated, the concentrations of 23 emerged as
significantly higher in pancreatic cancer compared to non-
malignant tissue. The most significant differences (P < .001)
were observed for Eotaxin, IP-10, MCP1, MCP3, MDC, IL-
1α, IL-1RA, IL-7, and IL-8. Interestingly, all but 3 (FGF-2,
RANTES and IL1β) of the 23 mediators that emerged as
significant when comparing pancreatic cancer to nonmalig-
nant tissue also emerged as significant when comparing
pancreatic cancer to pancreatitis. Together these data
suggest that pancreatic adenocarcinoma has a distinct
inflammatory milieu when compared to that of nonma-
lignant pancreatic tissues, including that of chronic
pancreatitis.
Elements of the intratumoral inflammatory milieu
strongly associate with the administration of neoadjuvant
cytotoxic chemotherapy
Dynamic changes accompanying the administration of
cytotoxic chemotherapy within the PC microenvironment
remain poorly described. In order to determine whether
differences within intratumoral inflammatory milieu associ-
ate with the administration of cytotoxic chemotherapy,
patients were dichotomized into groups based on the ad-
ministration of neoadjuvant therapy. Indeed, significantly
lower levels of intratumoral IL-8 were observed in PC spec-
imens from patients treated with neoadjuvant gemcitabine-
based regimens compared to those from treatment naïve
patients (median concentration 1129 pg/mg protein vs.
114 pg/mg protein; P = .003) (Table 2). Conversely, high
intratumoral concentrations of Flt-3 L and IL-2 correlated
with the administration of neoadjuvant chemotherapy.
Together these data suggest that the administration of cyto-
toxic chemotherapy alters the inflammatory microenviron-
ment in PC.
Poor histopathologic response to neoadjuvant chemo-
therapy appears to associate with poor clinical out-
comes, although this phenomenon continues to be debated
[28–30]. In order to determine if the intratumoral milieu
could offer insights into the degree of clinical response to
cytotoxic chemotherapy, histopathologic response to neo-
adjuvant chemotherapy was correlated to soluble mediator
concentrations. Clinically, resected PC specimens with a
poor histopathologic response to neoadjuvant therapy rep-
resent a group of treatment-resistant tumors. Indeed,
significantly higher levels of the pro-inflammatory cytokines
IL-1β and TNFα were observed in tumors from this
population compared to tumors displaying a moderate
to complete pathologic response to cytotoxic chemo-
therapy (Fig. 1). These preliminary data provide
rationale for the continued evaluation of potential bio-
logic mechanisms within the tumor microenvironment
by which resistance to cytotoxic chemotherapy is
maintained.
Variations within the intratumoral inflammatory milieu
correlate with clinicopathologic features
In order to determine whether patterns of soluble mediator
concentrations could offer further insights into the biology
of PC, the inflammatory milieu was evaluated with respect
to commonly used clinicopathologic parameters, such as
positive lymph node ratio, serum CA 19–9 concentrations,
tumor grade and tumor size. In our analysis of lymphatic
metastasis using positive lymph node ratio, elevated
Delitto et al. BMC Cancer  (2015) 15:783 Page 3 of 10
intratumoral EGF concentrations associated with a high de-
gree of lymphatic metastasis (ρ = 0.332, P = .048), while high
concentrations of IL-4 displayed the opposite trend,
correlating with reduced lymphatic metastasis (ρ = −0.377;
P = .023) (Table 3). Additionally, IFN-γ (ρ = 0.391; P = .022)
and RANTES (ρ = 0.475; P = .005) demonstrated significant
positive correlations with serum CA 19–9 levels. High
levels of IL-8 and IP-10 associated with larger tumors
(ρ = 0.336; P = .042 and ρ = 0.373; P = .023 with respect
to tumor size in cm). The inflammatory milieu was then
correlated with the degree of tumor differentiation ob-
served in malignant tissue. Significant associations between
poor tumor differentation and high concentrations of GM-
CSF, IL-15 and IL-8 were observed (Fig. 2). While these
patterns provide insights into potential relationships
between aspects of clinicopathological parameters and
inflammation, these parameters do not always correlate
with outcome.
We therefore aimed to determine if these known clinico-
pathologic predictors of outcome correlated with survival
in our cohort. One commonly used predictor of overall sur-
vival in resected pancreatic cancer is the ratio of lymph
nodes containing malignancy to the total number of lymph
nodes resected and examined [31]. Indeed in our cohort,
elevated positive lymph node ratios correlated strongly with
reduced overall survival (HR 55.8; P = .002) (Table 4). This
population therefore confirms the predictive nature of
lymphatic metastasis. However, associations between
Table 2 Intratumoral milieu correlates with the administration
of cytotoxic chemotherapy
Neoadjuvant Chemotherapy
No (n = 26) Yes (n = 10) P value
Flt3L 15.9 (1.6) 24.0 (3.5) .005
IL-1α 15.0 (2.6) 5.0 (0.9) .006
IL-8 1129 (197) 114 (35) .003
All significant comparisons are shown for which P < 0.05 using the Mann
Whitney U test












FGF-2 761 (221) 951 (187) 1674 (177) .009 .063
PDGF-BB 117 (46) 102 (48) 244 (63) .026 .022
VEGF 151 (46) 76 (20) 252 (59) .119 .046
Chemokines
Eotaxin 21.8 (12.8) 21.4 (12.9) 90.4 (16.3) <.001 .002
Fractalkine 55.1 (12.8) 43.0 (9.4) 71.1 (3.6) .010 .009
Gro 163 (67) 463 (296) 531 (87) .007 .043
IP-10 69 (33) 70 (32) 620 (148) <.001 <.001
MCP1 437 (136) 378 (104) 1615 (302) <.001 <.001
MCP3 4.7 (1.9) 2.5 (0.8) 16.6 (2.8) <.001 <.001
MDC 27 (11) 70 (36) 143 (17) <.001 .009
MIP-1α 14.3 (4.9) 16.9 (7.6) 37.9 (4.6) .001 .009
MIP-1β 22.1 (9.4) 14.3 (5.0) 38.4 (6.1) .007 .008
RANTES 766 (261) 1066 (228) 1929 (235) .032 .178
Cytokines
GM-CSF 4.1 (2.0) 1.4 (0.3) 14.0 (3.9) <.001 <.001
IFNα2 13.0 (2.7) 8.7 (2.3) 19.9 (2.4) .013 .012
IL-1α 1.8 (0.5) 3.2 (0.6) 12.2 (2.0) <.001 .003
IL-1RA 157 (144) 46 (21) 500 (96) <.001 <.001
IL-1β 0.6 (0.1) 0.9 (0.1) 1.3 (0.2) .032 .262
IL-6 13.3 (5.3) 5.8 (2.1) 71.8 (23.3) <.001 <.001
IL-7 3.9 (1.0) 4.5 (1.0) 10.4 (0.8) <.001 <.001
IL-8 160 (154) 61 (37) 848 (161) <.001 .002
IL-15 1.7 (0.2) 2.0 (0.3) 3.5 (0.4) .001 .021
TNFα 1.6 (0.7) 1.4 (0.4) 3.3 (0.4) .002 .010
Concentrations expressed as mean (SE) in units of pg/mg protein. All significant comparisons are shown for which P < 0.05 using the Mann Whitney U test
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survival and other commonly used prognostic parame-
ters such as microscopically positive resection margins
and poor tumor differentiation were not statistically
significant in this cohort (HR 1.96; P = .12 and HR
2.28; P = .053, respectively) (Table 4).
Variations in the inflammatory milieu within the tumor
microenvironment correlate with patient survival
Since the common clinicopathological data were poor at
predicting outcome, we next hypothesized that elements
within the inflammatory milieu harbor superior prognos-
tic value. The intratumoral milieu was correlated with
overall survival in all 36 patients with PC who underwent
surgical resection with curative intent. All patients had at
least 6 months of clinical follow-up. Associations between
the intratumoral milieu and overall survival were evalu-
ated using both Kaplan-Meier and Cox proportional
hazards models. Soluble mediators were first dichoto-
mized using median concentrations and evaluated by log-
rank test in a Kaplan-Meier model. FGF-2, MDC, IL-4
and Flt-3 L significantly correlated with prolonged survival
upon dichotomization (Table 5, Fig. 3). Due to the poten-
tial bias introduced from the artificial categorization of
values dichotomized at the median, a proportional hazards
model was employed, allowing for direct correlation of
intratumoral mediator concentration and survival. In this
manner, high levels of both G-CSF and PDGF-AA corre-
lated with reduced survival (HR 1.03; P = .016 and HR
3.51; P = .012, respectively) (Table 5).
Anecdotal observations of interest included: Four patients
with tumors which demonstrated distinctly high PDGF-AA
concentrations, at least double that of any other PC speci-
men, recurred within 6 months postoperatively. Further,
two patients with tumors containing G-CSF concentrations
over 5 times that of any other also recurred within
6 months, with one of these patients showing evidence of
metastatic disease as soon as two months postoperatively.
Conversely, two patients with tumors with undetectable
MIP-1α recurred within 6 months and three patients whose
tumors had the highest intratumoral MIP-1α concentra-
tions were recurrence-free between one and three years
postoperatively. Further, the patient with the highest intra-
tumoral TNFα concentration remains recurrence-free
34 months postoperatively.
Discussion
Due to the dismal clinical outcomes associated with pan-
creatic adenocarcinoma and the continued debate sur-
rounding therapeutic interventions, there is a tremendous
need for the development of tools that can supplement
current diagnostic and prognostic efforts. The extent of
genetic and phenotypic heterogeneity specific to PC repre-
sents a major obstacle to the clinical application of devel-
oping biomarkers in PC. Efforts to further understand
clinical observations regarding pathologic signaling within
the tumor microenvironment have provided a novel focus
that have led to major breakthroughs. Examples include
therapeutic successes following Nab-paclitaxel infusion that
is dependent upon SPARC expression in desmoplastic
tumor-associated stroma [32, 33], and consistent
Fig. 1 Th1-associated cytokines within the tumor microenvironment correlate with treatment resistance in PC. Distributions are displayed comparing
intratumoral concentrations of a IL-1β and b TNFα in homogenates of pancreatic adenocarcinoma with histopathologic response to neoadjuvant
chemotherapy. Bars represent mean values with standard error of the mean. *P < 0.05 for each association using the Mann Whitney U test
Table 3 Inflammatory milieu within the tumor microenvironment
correlates with clinicopathologic parameters in PC specimens
Clinical parameter Ligand Spearman coefficient P value
Positive Lymph Node Ratio EGF .332 .048
IL-4 -.377 .023
CA 19–9 (U/mL) IFN-ɤ .391 .022
RANTES .475 .005
Tumor Size (cm) IL-8 .336 .045
IP-10 .357 .033
All significant comparisons are shown for which P < 0.05
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observations that partial responses achieved from CD40 ag-
onists led to the infiltration of tumoricidal macrophages
into the local microenvironment [34, 35]. In order to fur-
ther understand clinically important paracrine signaling
pathways within this local microenvironment, the work
presented here has detected a unique inflammatory signa-
ture within pancreatic adenocarcinoma that is distinct from
that of chronic, benign inflammation. Further, several
members of this panel of markers were associated with spe-
cific clinicopathologic parameters, response to cytotoxic
chemotherapy, and overall survival.
The almost universal development of treatment resist-
ance and disease relapse following systemic cytotoxic or
targeted therapies has made survival in PC achievable in
only a small minority of patients. Mechanistically, che-
moresistant phenotypes have been reproduced in vitro.
However, the relevance of these findings to clinical practice
remains unclear. For example, gemcitabine resistance has
been linked to the expression of gemcitabine-metabolizing
proteins and DNA repair enzymes as well as the downregu-
lation of nucleoside transporters. However, the clinical
value of identifying these markers in resected PC specimens
has yielded conflicting results [36]. Here we demonstrate
that not only is the exposure to gemcitabine-based therapy
associated with a different inflammatory milieu within the
tumor, but also that differences in the milieu associate with
the degree of clinical response, whereby increased levels of
intratumoral IL1-β and TNF-α are associated with poor
histopathologic response to neoadjuvant therapy. These
findings further support a wealth of investigations linking
downstream NF-κB signaling to tumor progression and
chemoresistance [37].
The observation that EGF levels correlated with the
degree of lymph node metastasis is consistent with wide-
spread evidence implicating EGF signaling in cancer pro-
gression and metastasis, culminating in a phase three
trial employing EGFR inhibition in pancreatic cancer [3].
Conversely, high intratumoral concentrations of IL-4
displayed the opposite trend, correlating with reduced
lymphatic metastasis, whereby patients with tumors high
in IL-4 concentrations displayed roughly triple the sur-
vival of those with tumors expressing low levels of IL-4.
In light of this finding it is important to note that direct
stimulation of cancer cells with IL-4 generally results in
augmented growth and proliferation [38–40]. However,
this finding must be interpreted within the context of
IL-4 signaling within the microenvironment. Indeed,
constitutive IL-4 expressing cancers have demonstrated
reduced growth in vivo due to the induction of a robust
antitumor immune response [41]. Similarly, intratumoral
levels of IL-8 and GM-CSF were predictive of tumor
Fig. 2 Inflammatory milieu within the tumor microenvironment correlates with tumor grade. Intratumoral concentrations of a GM-CSF, b IL-8 and
c IL-15 demonstrated significant correlations with high tumor grade. *P < 0.05 for each association using the Mann Whitney U test
Table 4 Univariate analysis of overall survival
HR 95 % CI P value
Age (y) 1.01 0.98–1.05 .556
Neoadjuvant Therapy 1.08 0.43–2.68 .870
CA 19–9 (kU/mL) 1.38 0.83–2.29 .215
Major Vascular Resection 2.66 0.85–8.30 .093
R1 Resection 1.96 0.84–4.53 .118
Positive Lymph Node Ratio 55.8 4.35–714 .002*
Poor Tumor Differentiation 2.28 0.99–5.23 .053
Tumor Size (cm) 1.06 0.89–1.28 .506
Clinicopathologic parameters were analyzed in a Cox proportional hazards
model for 36 patients with surgically resected pancreatic adenocarcinoma.
Abbreviations: HR hazard ratio, CI confidence interval, y years, R1 resection
denotes a microscopically positive margin; Positive lymph node ratio refers to
the number of lymph nodes positive for malignancy divided by the total
number of lymph nodes examined; cm centimeters. *, P < .05
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grade while IL-8 levels were also positively associated
with tumor size. Again this is consistent with previous
findings that suggest that IL-8 and GM-CSF produced in
the tumor microenvironment promote immune evasion
in PC [42–44]. Interestingly, the administration of
cytotoxic chemotherapy was strongly associated with
significantly lower intratumoral IL-8 concentrations.
The investigation of the intratumoral inflammatory
milieu has therefore revealed consistent correlations
between IL-8 concentrations, histopathologic findings
and the administration of chemotherapy.
As alluded to above, several of these mediators could
also be used to predict survival. For instance, high intratu-
moral G-CSF levels correlated with reduced overall
survival, which is supported in literature relating myeloid-
derived suppressor cell infiltration to tumor progression
and angiogenesis [45]. Of particular interest is the pro-
longed survival observed in patients with high intratu-
moral FGF-2, known to stimulate fibroblast migration,
wound healing and generally thought to be a growth
factor which supports growing tumors. However, it is
generally accepted that FGF-2 is abundant in most tissues,
concentrated in basement membranes and at cell surfaces
in inactive forms. Tissue injury leads to FGF-2 activation
and subsequent promotion of wound healing processes
known to promote tumor growth, invasion and angiogen-
esis [46]. In this context, reduced FGF-2 concentrations in
tissue homogenates may paradoxically reflect increased
FGF-2 activation, which would lead to the expected find-
ings of reduced survival.
The inability to follow the intratumoral inflammatory
milieu over time represents a significant limitation to this
type of analysis, as this information will be critical to elu-
cidating the relationship between local inflammation and
treatment strategies in PC. In addition, stratification of
long-term survival into treatment-naïve and treatment-
exposed tumors will be essential in validating these rela-
tionships. However, this analysis currently lacks the power
to dichotomize in this fashion. While grouping mediators
into functionally relevant categories may address our
current lack of power, the pleiotropic nature of these sol-
uble mediators may lead to improper interpretations in the
absence of functional analyses. Further, it has not escaped
our notice that VEGF demonstrated no correlation with
survival in this analysis. The extensive body of work asso-
ciating VEGF signaling with angiogenesis and tumor
progression has led many groups to investigate potential
correlations between VEGF expression and survival in
PC. Subsequent analyses have yielded conflicting results
[47–49]. Importantly, this is not the first clinical cohort
to demonstrate a nonsignificant correlation between
intratumoral VEGF levels and overall survival in PC.
Conclusions
In summary, pancreatic adenocarcinoma is a devastating
malignancy with an extremely poor prognosis. High ratios
of tumor stroma to cancer cells plague the sensitivity of
cytologic diagnosis of PC; In fact, even direct pathologic
analysis of PC biopsies can yield inconsistent results with
high interobserver variability [50]. Highly specific, reliable
biochemical signatures obtained from these small samples
that improve diagnostic sensitivity could dramatically im-
prove the clinical care of PC patients. Further, treatment
algorithms for PC in the absence of metastasis are cur-
rently anatomic based and lack attention to variations in
biology. Thus, there is further need to develop accurate
biomarkers capable of predicting response to systemic
therapies or the futility of surgical or radiation therapy.
Table 5 Soluble mediators detected within the PC microenvironment correlate with prognosis
Dichotomized at median concentration Univariate PH model Multivariate PH model
Median OS (Low) Median OS (High) P value HR (95 % CI) P value HR (95 % CI) P value
EGF 10.4 11.0 .165 1.23 (0.98–1.54) .078 1.10 (.86–1.42) .439
G-CSF 18.3 7.5 .064 1.03 (1.01–1.06) .016* 1.02 (1.00–1.05) .071
PDGF-AA 18.7 8.9 .170 3.51 (1.32–9.31) .012* 2.72 (1.00–7.40) .050*
IL-6 11.0 10.4 .500 12.0 (0.85–172) .066 6.10 (0.39–96.13) .198
FGF-2 7.1 20.7 .010* 0.60 (0.37–0.97) .038* 0.59 (0.37–0.93) .024*
TNFα 7.5 18.3 .085 0.78 (0.63–0.98) .031* 0.79 (0.64–0.97) .027*
MIP-1α 10.4 14.9 .352 0.98 (0.96–1.00) .036* 0.98 (0.97–1.00) .029*
IL-4 7.6 20.7 .008* 0.85 (0.70–1.04) .112 0.26 (0.75–1.08) .902
Flt-3 L 7.1 18.7 .037* 0.95 (0.88–1.01) .103 0.94 (0.86–1.02) .113
MDC 7.6 20.7 .049* 0.01 (0–1.37) .065 0.01 (0–2.24) .098
Eotaxin 7.5 18.7 .055 0.03 (0–15.2) .263 0.09 (0–47.9) .454
Soluble mediators were dichotomized at median concentrations and survival was evaluated using Kaplan-Meier analysis with P values determined using the log-rank
test (left). Associations between soluble mediator concentrations and survival were then evaluated in a continuous fashion using a Cox proportional hazards model
(middle). Finally, concentrations were evaluated in a multivariate Cox proportional hazards model with positive lymph node ratio (right). Abbreviations: PH proportional
hazards, OS overall survival, HR hazard ratio, CI confidence interval. *, P < .05
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Unfortunately, the current literature is characterized by
marked variability between individual studies as to the
relative prognostic impact of several biomarkers in PC.
Here, in contrast to studies that evaluated these properties
using a single or a couple biomarkers, we have identified
novel relationships between tissue examination and clin-
ical outcome by quantitatively evaluating the milieu of the
tumor microenvironment utilizing fresh pancreatic surgi-
cal specimens. It is important to note that even though
some of these associations are counterintuitive based on
the currently understood biology, the greater context and
complexity of the tumor microenvironment in PC is not
currently appreciated. Thus, these data combined with a
better understanding of the context-dependence of in-
flammatory signaling, may eventually offer the opportun-
ity to identify patterns that improve interpretations in
cancer and emphasize the importance of investigating the
tumor microenvironment as a whole. Nonetheless, results
Fig. 3 Elements of the inflammatory milieu within the tumor microenvironment have prognostic value. Kaplan-Meier curves are plotted for a FGF-2,
b MDC, c Flt-3 L and d IL-4 based on cutoffs at median cytokine concentrations in 36 pancreatic adenocarcinoma specimens. The log-rank test was
used to compare differences. Significance was considered for those in which P < 0.05
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presented here exhibit a high degree of reproducibility
and provide rationale to prospectively evaluate these
markers as diagnostic and prognostic tools.
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